Company / SG&A Expense
Decoy Therapeutics Inc. SG&A Expense History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$6.1M
FY2022
5-year range
$2.3M / $19.9M
FY2018-FY2022
Trend
-0.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 7 years, ranging from $2M in FY2019 to $20M in FY2018.
Based on SEC 10-K filings.
$6M in FY2022 with a 5-year CAGR of -18.0%.
Improved from $8M to $6M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +37.5%
- 5-Year CAGR
- -18.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -18.0%, indicating a declining trend.
- In FY2022, sg&a expense decreased 0.0% year-over-year.
- Peak sg&a expense was recorded in FY2018.
- Lowest sg&a expense in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $6.1M | -0.0% |
| FY2021 | $6.1M | -20.8% |
| FY2020 | $7.7M | +228.4% |
| FY2019 | $2.3M | -88.2% |
| FY2018 | $19.9M | +20.6% |
| FY2017 | $16.5M | +309.0% |
| FY2016 | $4.0M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026